Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: Establishment of a novel logistical regression model

Hepatology International

Volumn 6, Issue 4, 2012, Pages 735-743

  Ma, Ke ^a   Guo, Wei ^a   Han, Meifang ^a   Chen, Guang ^a   Chen, Tao ^a   Wu, Zenguang ^a   Yang, Daofeng ^a   Huang, Jiaquan ^a   Huang, Yuancheng ^a   Zhao, Xiping ^a   Tian, Deying ^a   Song, Jianxin ^a   Qi, Junying ^a   Ning, Qi ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acute on chronic liver failure; Entecavir; Hepatitis B virus; Scoring model

Indexed keywords

ENTECAVIR; PROTHROMBIN; VIRUS DNA;

ACUTE ON CHRONIC LIVER FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; INFECTION CONTROL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME;

EID: 84874118691     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-012-9344-9     Document Type: Article

References (46)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337: 1733-1745.
2. Poland GA, Jacobson RM. Clinical practice: Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004;351: 2832-2838.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001; 34:1225-1241.
4. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature. 2004;430:242-9.
5. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004;350:1118-1129.
6. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132: 2557-2576.
7. Fattovich G. Progression of hepatitis B and C of hepatocellular carcinoma in Western countries. Hepatogastroenterology. 1998; 45:1206-1213.
8. Lok AS. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis. 1992;10:46-52.
9. Ke WM, Ye YN, Huang S. Discriminant function for prognostic indexes and probability of death in chronic severe hepatitis B. J Gastroenterol 2003;38:861-864.
10. Zou Z, Chen J, Xin S, et al. Features of chronic severe hepatitis in 520 cases with chronic severe hepatitis. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2002;16:246-248.
11. Wang Y, Chen Y, Gu C, et al. Reevaluation of the nomenclature and diagnostic criteria in 477 patients with severe hepatitis. Zhonghua Gan Zang Bing Za Zhi 2000;8:261-263.
12. Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific association for the study of the liver (APASL). Hepatol Int 2009;3: 269-282.
13. Jalan R, Williams R. Acute-on-chronic liver failure: Pathophysiological basis of therapeutic options. Blood Purif 2002;20: 252-261.
14. Wu Z, Han M, Chen T, et al. Acute liver failure: Mechanisms of immune-mediated liver injury. Liver International. 2010;30: 782-794.
15. Marsden PA, Ning Q, Fung LS, et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest 2003; 112:58-66.
16. Zou Y, Chen T, Han M, et al. Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J Immunol 2010;184:466-475.
17. Sen S, Mohensi S, Sjodin L, et al. Baseline SOFA score and its lack of early improvement accurately predicts mortality in patients with acute-on-chronic liver failure. Hepatology. 2004;40:489A.
18. Stauber R, Stadlbauer V, Struber G, et al. Evaluation of four prognostic scores in patients with acute-on-chronic liver failure. J Hepatol 2006;44:S69-70.
19. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000;33:301-307.
20. Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006;13:256-263.
21. Dai CY, Yu ML, Hsieh MY, et al. Early response to lamivudine therapy in clinically noncirrhotic chronic hepatitis B patients with decompensation. Liver Int 2007;27:1364-1370.
22. Chan HL. Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: Is it too late? Dig Dis Sci 2010;55:2126-2128.
23. Cui YL, Yan F, Wang YB, et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci 2010;55:2373-2380.
24. Chen J, Han JH, Liu C, et al. Short-term entecavir therapy of chronic severe hepatitis B. Hepatobiliary Pancreat Dis Int 2009; 8:261-266.
25. Chan HL, Tsang SW, Hui Y, et al. The role of Lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepatitis 2002;9:424-428.
26. Tsubota A, Arase Y, Suzuki Y, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2005;20:426-432.
27. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
28. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, editor. The Liver and Portal Hypertension. Philadelphia: W.B Saunders Co; 1964. p. 1-85.
29. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60: 646-649.
30. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
31. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96.
32. Yu JW, Wang GQ, Zhao YH, et al. The MELD scoring system for predicting prognosis in patients with severe hepatitis after plasma exchange treatment. Hepatobiliary Pancreat Dis Int. 2007; 6:492-496.
33. Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: Moving toward evidence-based transplantation policy. Liver Transpl 2002;8:851-858.
34. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology. Diagnostic and treatment guidelines for liver failure. Chin J Hepatol 2006;14:643-646.
35. Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: An evolution from child to MELD. Hepatology. 2001;33: 473-475.
36. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395-403.
37. Zhu C, Sun Y, Luo X, et al. Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice. Hum Gene Ther 2006;17:589-600.
38. Zhu CL, Yan WM, Zhu F, et al. Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. World J Gastroenterol 2005;11:6936-6940.
39. Han M, Yan W, Guo W, et al. Hepatitis B virus-induced hFGL2 transcription is dependent on c-Ets-2 and MAPK signal pathway. J Biol Chem 2008;283:32715-32729.
40. Armbrust T, Kreissig M, Tron K, et al. Modulation of fibronectin gene expression in inflammatory mononuclear phagocytes of rat liver after acute liver injury. J Hepatol 2004;40:638-645.
41. Sanchez MJ, Buti M, Homs M, et al. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 2009;51: 1091-1096.
42. Jochum C, Gieseler RK, Gawlista I, et al. Hepatitis B-associated acute liver failure: Immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion. 2009;80:235-240.
43. Tsang SW, Chan HL, Leung NW, et al. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment Pharm Therapeut 2001;15:1737-1744.
44. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-470.
45. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96.
46. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864-871.